Allergan plc (NYSE:AGN) Launches Online Resource To Support Patients With IBS-D

364
Allergan

Allergan plc (NYSE:AGN) has launched IBSDonTract.com, an online resource targeting people who are battling with the irritable bowel syndrome with diarrhea (IBS-D). IBS-D is a functional bowel disorder that comes with frequent diarrhea and chronic abdominal pain. It affects approximately 15 million adults in the United States.

The new website is part of the Allergan’s efforts to educate patients and the public about IBS-D. It includes crucial information about symptoms of IBS-D, how to manage the condition, and tips to help the patients communicate effectively with healthcare providers about IBS-D.

Gavin Corcoran, a medical director who is also a fellow of the American College of Physicians and the Chief Medical Officer at Allergan, said that IBS-D has so many negative impacts on a patient’s daily life. He added that due to embarrassment or being unsure of the symptoms, most patients take too long before seeing a doctor.

Gavin explained further that IBSDonTract.com is a crucial resource that will offer a better understanding of IBS-D to patients and also help them to know viable options in dealing with the condition. Also, the website will explain the importance of seeking medical attention during the early stages of IBS-D, as this will shorten the duration between onset of symptoms and the effective disease management.

Shocking statistics on IBS-D

Findings from IBS in America Survey, a comprehensive survey that was conducted by American Gastroenterological Association (AGA) which involved more than 3,200 patients and 300 physicians, reveal that 66 percent of patients take a full year before seeing a doctor. Also, the survey showed that 11 percent of IBS-D patients wait a decade or more to seek medical attention regarding the condition.

Since IBSDonTract contains important information regarding this condition, it could help patients track their symptoms using the self-assessment tool. They may also learn from the doctor discussion guide available on the site.

IBS-D weakens the patient and there are limited therapeutic options regarding the management of chronic symptoms. It is also associated with economic burden, lost productivity, and decreased quality of life.

An ad to help with our costs